4 results match your criteria: "University of Genova - Azienda Policlinico IRCCs San Martino[Affiliation]"
RAPP-children: A new tool for assessing quality of life in patients with asthma and rhinitis.
Clin Exp Allergy
June 2020
Institute for Biomedical Research and Innovation, National Research Council, Palermo, Italy.
Background: RhinAsthma Patient Perspective (RAPP) is a short, validated questionnaire for assessing health-related quality of life (HRQoL) in adult patients with comorbid asthma and rhinitis, while a paediatric version is still not available.
Objective: The current study aimed to develop and validate the RAPP-children questionnaire.
Methods: RAPP-children was derived by combining RhinAsthma-children subscales into five unique items.
Cross-cultural adaptation and validation of the RhinAsthma Patient Perspective (RAPP) in Spanish.
Allergol Immunopathol (Madr)
November 2020
Department of Internal Medicine, Respiratory Diseases and Allergy Clinic, University of Genova - Azienda Policlinico IRCCs San Martino, Genova, Italy; Personalized Medicine, Asthma and Allergy Clinic, Humanitas Research Hospital, Milan, Italy.
Objective: the RhinAsthma Patient Perspective (RAPP) is the only available tool to assess HRQoL in daily practice. The aim of this study is to cross-culturally validate the RAPP in Spanish.
Methods: The RAPP was translated into Spanish.
The Portuguese version of Rhinitis and Asthma Patient's Perspective (RAPP): Validation and assessment.
Pulmonology
March 2020
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Background: Allergic rhinitis (AR) and asthma are two common chronic diseases that often coexist. There is a need for a validated tool to evaluate HRQoL of Portuguese speakers with asthma and/or rhinitis patients in clinical practice.
Objectives: To adapt and validate RhinAsthma Patient Perspective (RAPP) in Portuguese.
Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives.
Patient Relat Outcome Meas
August 2018
Department of Internal Medicine, Respiratory Diseases and Allergy Clinic, University of Genova - Azienda Policlinico IRCCs San Martino, Genova, Italy.
Approximately 5%-10% of asthmatics suffer from severe asthma. New biological treatments represent a great opportunity to reduce asthma burden and to improve asthma patients' lives. Reslizumab will soon be available in several European countries.
View Article and Find Full Text PDF